Neal Shore, MD, FACS, speculates on how the utilization of AR-pathway inhibitors and docetaxel in earlier lines of mCRPC treatment has also influenced treatment with cabazitaxel.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.